Skip to main content
Fig. 2 | Clinical and Translational Allergy

Fig. 2

From: Cost utility analysis of the SQ® HDM SLIT-tablet in house dust mite allergic asthma patients in a German setting

Fig. 2

Overview of the structure of the analysis. A cost utility analysis was undertaken to assess the impact of ACARIZAX on allergic asthma patients taking pharmacotherapy. Two treatment options were included; ACARIZAX plus pharmacotherapy, and placebo plus pharmacotherapy. A nine year time horizon was used, with ACARIZAX patients given treatment for 3 years. Over the nine year time horizon ACARIZAX patients accumulated 6.16 QALYs on average, at a mean cost of €5658, compared to an average of 5.50 QALYs at a mean cost of €2985 for pharmacotherapy only patients. This equates to an incremental cost-effectiveness ration (ICER) of €4041, substantially lower than the threshold value of €40,000 adopted here. This indicates that ACARIZAX is a cost-effective treatment option

Back to article page

Clinical and Translational Allergy

ISSN: 2045-7022

Contact us